Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

ESC heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34544205
ESC Heart Fail. 2021 Sep 20; doi: 10.1002/ehf2.13622. Epub 2021 Sep 20.

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim...

Cite
Kolwelter J, Bosch A, Jung S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;doi: 10.1002/ehf2.13622.
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, . https://doi.org/10.1002/ehf2.13622
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC heart failure vol. (2021). doi: https://doi.org/10.1002/ehf2.13622
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021 Sep 20; doi: 10.1002/ehf2.13622. Epub 2021 Sep 20. PMID: 34544205.
Copy Download .nbib Format: NLM
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.

Cardiovascular diabetology

Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE.
PMID: 34481498
Cardiovasc Diabetol. 2021 Sep 04;20(1):178. doi: 10.1186/s12933-021-01358-8.

BACKGROUND: Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.METHODS: Patients (N = 97) with type 2 diabetes were randomized to...

Cite
Ott C, Jung S, Korn M, et al. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021;20(1):178doi: 10.1186/s12933-021-01358-8.
Ott, C., Jung, S., Korn, M., Kannenkeril, D., Bosch, A., Kolwelter, J., Striepe, K., Bramlage, P., Schiffer, M., & Schmieder, R. E. (2021). Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovascular diabetology, 20(1), 178. https://doi.org/10.1186/s12933-021-01358-8
Ott, Christian, et al. "Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine." Cardiovascular diabetology vol. 20,1 (2021): 178. doi: https://doi.org/10.1186/s12933-021-01358-8
Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021 Sep 04;20(1):178. doi: 10.1186/s12933-021-01358-8. PMID: 34481498; PMCID: PMC8418746.
Copy Download .nbib Format: NLM
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

ESC heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34544205
ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20.

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim...

Cite
Kolwelter J, Bosch A, Jung S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6):5327-5337doi: 10.1002/ehf2.13622.
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, 8(6), 5327-5337. https://doi.org/10.1002/ehf2.13622
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC heart failure vol. 8,6 (2021): 5327-5337. doi: https://doi.org/10.1002/ehf2.13622
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20. PMID: 34544205.
Copy Download .nbib Format: NLM
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

ESC heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34544205
ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20.

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim...

Cite
Kolwelter J, Bosch A, Jung S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6):5327-5337doi: 10.1002/ehf2.13622.
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, 8(6), 5327-5337. https://doi.org/10.1002/ehf2.13622
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC heart failure vol. 8,6 (2021): 5327-5337. doi: https://doi.org/10.1002/ehf2.13622
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20. PMID: 34544205; PMCID: PMC8712907.
Copy Download .nbib Format: NLM
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.

Cardiovascular diabetology

Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34753480
Cardiovasc Diabetol. 2021 Nov 09;20(1):219. doi: 10.1186/s12933-021-01410-7.

BACKGROUND: Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients with chronic heart failure (CHF), increased myocardial...

Cite
Pietschner R, Kolwelter J, Bosch A, et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20(1):219doi: 10.1186/s12933-021-01410-7.
Pietschner, R., Kolwelter, J., Bosch, A., Striepe, K., Jung, S., Kannenkeril, D., Ott, C., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovascular diabetology, 20(1), 219. https://doi.org/10.1186/s12933-021-01410-7
Pietschner, R, et al. "Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure." Cardiovascular diabetology vol. 20,1 (2021): 219. doi: https://doi.org/10.1186/s12933-021-01410-7
Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021 Nov 09;20(1):219. doi: 10.1186/s12933-021-01410-7. PMID: 34753480; PMCID: PMC8579532.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries